Drug Type Recombinant protein |
Synonyms IL2 CD25 BristolMyers Squibb, IL2/CD25 BristolMyers Squibb, Interleukin2/interleukin2 receptor alpha fusion protein BristolMyers Squibb |
Target |
Action stimulants, agonists |
Mechanism IL-2 stimulants(Interleukin-2 stimulants), IL2RA agonists(Interleukin-2 receptor alpha chain agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autoimmune Diseases | Phase 1 | United States | 19 Jan 2021 |